Related Experiment Video
Updated: Aug 14, 2026
06:21
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Dynamic feedback between IL-6 and TWIST1 drives pancreatic cancer progression
Miao Yu1,2, Enlai Huang1,2, Mingxin Su1,2
1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Translational Gastroenterology and Hepatology
|August 13, 2026
Summary
Interleukin-6 (IL-6) and TWIST1 form a feedback loop promoting pancreatic cancer. Targeting this IL-6/miR-543/TWIST1 axis with drugs like Tocilizumab may block pancreatic ductal adenocarcinoma progression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Interleukin-6 (IL-6) and TWIST1 are key regulators in pancreatic ductal adenocarcinoma (PDAC) progression.
- The precise dynamic interaction between IL-6 and TWIST1 in PDAC remains incompletely understood.
- Elucidating this interaction is crucial for understanding PDAC pathogenesis.
Purpose of the Study:
- To investigate the interaction between IL-6 and TWIST1 in PDAC.
- To explore the molecular mechanisms underlying this interaction and its role in PDAC progression.
- To identify potential therapeutic targets within this signaling pathway.
Main Methods:
- Analysis of IL-6, IL-6R, and TWIST1 expression in 66 PDAC patient specimens.
- Integrative bioinformatics and experimental validation to identify upstream regulators.
- Quantitative PCR, western blotting, and luciferase assays to verify the IL-6/miR-543/TWIST1 feedback circuit.
- Chromatin immunoprecipitation and in vivo xenograft models to assess functional relevance and therapeutic blockade.
Main Results:
- Elevated IL-6, IL-6R, and TWIST1 expression correlated with poor prognosis in PDAC patients.
- miR-543 was identified as a key mediator linking IL-6 signaling to TWIST1.
- A positive feedback loop was confirmed where IL-6 promotes TWIST1 via miR-543, and TWIST1 upregulates IL-6, driving PDAC cell migration, invasion, and proliferation.
- Tocilizumab effectively inhibited this feedback loop and attenuated PDAC progression in vivo.
Conclusions:
- The IL-6/miR-543/TWIST1 axis constitutes a critical feedback circuit driving PDAC malignancy.
- Targeting this axis therapeutically offers a promising strategy to impede pancreatic cancer progression.
- Understanding this pathway provides insights into novel therapeutic interventions for PDAC.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...